COIOSDeep risk insights through multi-disciplinary research across the globe
woman in black long sleeve shirt and black pants running on track field during daytime
Item new Peer-reviewed Added

Tirzepatide reduced BMI by 18.5% over 72 weeks in adolescents with obesity

In 160 adolescents with obesity, weekly tirzepatide cut BMI by 18.5% over 72 weeks, against a 0.5% rise with placebo.

This phase 3 trial tested weekly tirzepatide in 160 adolescents with obesity, or overweight plus a complication. Across 31 centres in six countries, they were randomised 2:1, double-blind, to tirzepatide or placebo plus lifestyle intervention. At week 72, BMI fell 18.5% with tirzepatide and rose 0.5% with placebo, a 19.0-point difference. BMI fell by at least 5% in 79.6% on tirzepatide and 28.5% on placebo. All 10 key secondary outcomes, including body weight, waist circumference and physical functioning, favoured tirzepatide. Adverse events and discontinuations were recorded, but the abstract supplied ends before reporting them.

Why it is interesting: Tirzepatide is approved for obesity management in adults. This placebo-controlled trial reports its 72-week effect on BMI in adolescents.

Source
JAMA, 15 November 2026
DOI
10.1001/jama.2026.23420
Type
Peer-reviewed article
Design
Phase 3 randomised double-blind placebo-controlled trial, 160 adolescents aged 12 to <18, 2:1 allocation, 72 weeks, 31 centres, 2023-2026
Verdict
New finding
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today